CD73 Inhibitor Pipeline Review

CD73 Inhibitor Pipeline Review

Targets: CD73; 5’-nucleotidase or NT5E

Product Category: Antibody; RNA; Small Molecule

This product provides basic information on investigational antibodies, antisense and small molecules inhibiting CD38.

This product consists of:

• Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
• Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
• One-month online access to La Merie Publishing’s database for investigational therapies targeting CD73 (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

CD73 (5’-nucleotidase or NT5E) is a cell surface enzyme responsible for the rate limiting step in adenosine production; the conversion of adenosine monophosphate (AMP) into adenosine. Immunosupressive adenosine contributes to immune evasion in solid tumors by accumulating within the tumor microenvironment and thereby inhibiting immune effector cells (e.g., CD8⁺ T cells). CD73 expression levels correlate with a worse prognosis in specific cancer types, including breast cancer. Adenosine production via CD73 can be therapeutically inhibited by two independent mechanisms: (1) enzyme inhibition, and (2) receptor internalization and subsequent degradation. The reduction of adenosine restores immune function. Once the immunosuppressive effects of adenosine are removed, activation of antitumor immune cells may be restored resulting in tumor cell death.